Strategies for having a more effective and less toxic CAR T-cell therapy for acute lymphoblastic leukemia.

ABSTRACT: In the recent years, using genetically modified T cells has been known as a rapid developing therapeutic approach due to the heartwarming results of clinical trials with patients suffering from relapsed or refractory (R/R) hematologic malignancies such as R/R Acute Lymphoblastic Leukemia (R/R ALL). One of these renowned approaches is Chimeric antigen receptors (CARs). CARs are synthetic receptors with the ability to be expressed on the surface of T lymphocytes and are specifically designed to target a tumor-associated antigen (TAA) of interest. CAR-expressing T cells have the capability of proliferating and maintaining their immunological functionality in the recipient body but like any other therapeutic approach, the safety, effectiveness, and specificity enhancement of CAR T cells still

SUBMITTER: Hashem Boroojerdi M 

PROVIDER: S-EPMC7549730 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature